Last reviewed · How we verify
PD1/PDL1 inhibitor
This drug blocks the PD-1/PD-L1 immune checkpoint pathway to reactivate T cells and enhance anti-tumor immunity.
This drug blocks the PD-1/PD-L1 immune checkpoint pathway to reactivate T cells and enhance anti-tumor immunity. Used for Advanced or metastatic solid tumors (specific indication under investigation in Phase 3).
At a glance
| Generic name | PD1/PDL1 inhibitor |
|---|---|
| Also known as | Administration of PD1/PDL1 inhibitor through vein or interventional technique. |
| Sponsor | Second Affiliated Hospital of Guangzhou Medical University |
| Drug class | PD-1/PD-L1 inhibitor |
| Target | PD-1 and/or PD-L1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
PD-1/PD-L1 inhibitors work by blocking the interaction between programmed death ligand 1 (PD-L1) on tumor cells and programmed death receptor 1 (PD-1) on T cells. This blockade prevents tumor-mediated immune suppression, allowing T cells to recognize and attack cancer cells. The drug restores the body's natural anti-tumor immune response.
Approved indications
- Advanced or metastatic solid tumors (specific indication under investigation in Phase 3)
Common side effects
- Fatigue
- Decreased appetite
- Nausea
- Immune-related pneumonitis
- Immune-related hepatitis
- Immune-related colitis
- Rash
Key clinical trials
- Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy (PHASE1)
- HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer (NA)
- Correlation Vitamin D Level to Endocrine Autoimmune Toxicity Due to Immune Checkpoint Inhibitors
- Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial (PHASE2)
- Neoadjuvant PD-1 Inhibitor and EGFR Inhibitor in Locally Advanced Cutaneous Squamous Cell Carcinoma (PHASE2)
- Neoadjuvant Sacituzumab Govitecan Plus Tagitanlimab for Resectable Head and Neck Squamous Cell Carcinoma (PHASE2)
- A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC (PHASE1, PHASE2)
- Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PD1/PDL1 inhibitor CI brief — competitive landscape report
- PD1/PDL1 inhibitor updates RSS · CI watch RSS
- Second Affiliated Hospital of Guangzhou Medical University portfolio CI